Angelalign’s 1H26 preliminary results beat Morgan Stanley and consensus across core metrics
Angelalign Technology said in a preliminary announcement that its core first-half 2026 (1H26) indicators—including revenue, shipments in China and overseas markets, and net profit—will all exceed Morgan Stanley’s expectations and broader market consensus.
Angelalign Technology said in a preliminary announcement that its core first-half 2026 (1H26) indicators—including revenue, shipments in China and overseas markets, and net profit—will all exceed Morgan Stanley’s expectations and broader market consensus.
Morgan Stanley said the results point to improving brand recognition and a faster-than-expected reduction in overseas losses.
Morgan Stanley’s thesis is that China’s clear-aligner market continues to gain penetration and that the company’s overseas expansion is entering a harvest phase. The pace of overseas loss reduction may have been underestimated by the market, and the preliminary announcement could support a valuation recovery, according to the bank.
The note identifies a recovery in the domestic business, overseas expansion and margin improvement as potential upside factors. Government-led volume-based procurement, competition and slower-than-expected overseas volume growth are cited as the main downside risks.
The next catalysts are the details in Angelalign’s formal 1H26 results, new-order data from overseas markets and progress on volume-based procurement policies.
Morgan Stanley’s conclusion is that Angelalign’s 1H26 preliminary results beat expectations across the board, with overseas losses narrowing faster than expected.
Morgan Stanley said the results point to improving brand recognition and a faster-than-expected reduction in overseas losses.
Morgan Stanley’s thesis is that China’s clear-aligner market continues to gain penetration and that the company’s overseas expansion is entering a harvest phase. The pace of overseas loss reduction may have been underestimated by the market, and the preliminary announcement could support a valuation recovery, according to the bank.
The note identifies a recovery in the domestic business, overseas expansion and margin improvement as potential upside factors. Government-led volume-based procurement, competition and slower-than-expected overseas volume growth are cited as the main downside risks.
The next catalysts are the details in Angelalign’s formal 1H26 results, new-order data from overseas markets and progress on volume-based procurement policies.
Morgan Stanley’s conclusion is that Angelalign’s 1H26 preliminary results beat expectations across the board, with overseas losses narrowing faster than expected.